Objectives: This presentation shares findings from a large-scale retrospective study investigating exosome therapy for androgenic alopecia in 300 subjects. Evaluating the impact of topical exosome application post-microneedling, the study assessed hair density, shaft diameter, and safety outcomes. The results from this comprehensive 300-subject study highlight exosome therapy’s regenerative potential, its role in follicular restoration, and the need for standardized protocols to optimize clinical application in hair loss treatment.

Introduction: Exosome therapy has emerged as a promising option in the management of androgenic alopecia. While early studies have shown encouraging results, large subject groups are needed to confirm both safety and efficacy. This retrospective study examines outcomes in 300 patients treated with exosomes applied topically after microneedling. Beyond overall hair regrowth, we focused on changes in hair density, shaft diameter, and clinical safety, aiming to clarify the role of exosomes in follicular restoration and future treatment planning.

Materials / method: This multicenter, multi-practitioner retrospective study evaluated outcomes in 300 subjects diagnosed with androgenic alopecia across sexes, age groups, races, and varying stages of hair loss. Each subject received topical exosome therapy following microneedling at 0.3 to 0.5 millimeters in depth. Treatments were administered on days 1, 15, 45, 75, and 105. Trichoscopy and digital imaging were used at baseline and follow-up visits to assess hair density, shaft diameter, and any adverse effects.

Results: Significant improvements were observed in both hair density and shaft diameter following exosome application. On average, subjects experienced a 20 percent increase in hair density and an 18 percent increase in shaft thickness by day 45. No subjects reported discomfort, irritation, or adverse reactions during the study period. These findings support both the efficacy and tolerability of exosome therapy when used in conjunction with microneedling, even in a diverse population with varying hair types and levels of hair loss.

Conclusion: This large scale retrospective study underscores the regenerative promise of exosome therapy in treating androgenic alopecia. Notable increases in hair density and shaft diameter confirm its clinical relevance, while the absence of adverse effects supports its safety profile. These findings also highlight the urgent need for standardized protocols to ensure consistent outcomes across practices. When incorporated into structured programs, exosome therapy may offer a reliable and noninvasive solution for long term scalp and follicular health.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability